Sign in
Not yet taking people in United StatesNo phase

Comparing less and more frequent check-ups after bladder tumor removal in veterans

Compares lower and higher intensity follow-up in veterans with high-grade early bladder cancer.

Key facts

Who runs it
VA Office of Research and Development
Where
White River Junction, United StatesSee the site
Trial code
Registry title
VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors
Status
Not yet recruiting
People taking part
2,482 people, planned
Starts
1 Jan 2027
Expected to end
1 Jan 2037
Type of study
Interventional, 2 groups
Treatments tested
  • Low Intensity Surveillance
  • High Intensity Surveillance
Record updated
13 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for veterans with high-grade bladder cancer that has not grown into the bladder muscle, whose first cystoscopy after surgery showed no cancer. It compares less frequent and more frequent check-ups.

Age
18 years or older
Sex
All sexes can join
Disease stage
High-grade non-muscle invasive bladder cancer: stage Ta, stage T1, or carcinoma in situ, confirmed by a recent biopsy or surgery to remove the tumor
Earlier treatment
Must have had a recent biopsy or tumor removal from the bladder. Treatment since then must follow the VA National Oncology Bladder Cancer Clinical Pathway, or a reason for not following it must be documented.
Biomarker or test result
The first check-up cystoscopy after surgery (the 3-month cystoscopy) must show no cancer, with a normal or atypical urine cytology test.

Main reasons for not taking part

  • History of muscle-invasive bladder cancer
  • Cancer of the ureter, renal pelvis, prostate or urethra with current or untreated disease
  • Imaging that raises concern for cancer that has spread
  • Known pregnancy at enrolment
  • Cannot follow up for at least 5 years or is in another drug or device study

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • VA patients with a history of high-grade non-muscle invasive urothelial carcinoma of the bladder (Inclusion of non-Veterans only allowed if they already receive clinical care at a VA medical center, e.g., via the CHAMPS program)
  • Local pathology report from recent biopsy or resection confirming high-grade non-invasive urothelial carcinoma (high-grade stage Ta), high-grade urothelial carcinoma with invasion into the subepithelial connective tissue (high-grade stage T1), or carcinoma in situ (stage CIS) Note: Participants do not have to have a new diagnosis of urothelial carcinoma. Participants who had a resection of a recurrent urothelial carcinoma are eligible if they meet inclusion / exclusion criteria
  • Bladder cancer treatment since recent biopsy or resection that is in line with VA National Oncology Bladder Cancer Clinical Pathway (e.g., underwent re-resection of T1 disease, administration of intravesical therapy if indicated, or documented reason why Pathway was not followed)
  • No evidence of bladder cancer recurrence at first surveillance cystoscopy after most recent resection or biopsy showing urothelial carcinoma (referred to by "3-month cystoscopy" in the protocol), defined as negative cystoscopy AND negative or atypical urine cytology; Notes:
  • a re-resection TURBT performed per VA National Oncology Bladder Cancer Clinical Pathway or per local urology clinician judgement is not considered a surveillance cystoscopy. In that setting, the first cystoscopy following that re-resection TURBT will be the "3-month cystoscopy."
  • atypical cytology is not of concern in this population, as it frequently can be seen secondary to instrumentation, inflammation, or bacterial colonization
  • Ability to consent in English or Spanish
  • Stated willingness to comply with all study procedures

Who cannot take part

  • Dual enrollment in an interventional drug or device study
  • History of urothelial carcinoma of the ureter or renal pelvis status post endoscopic treatment or with evidence of current upper tract disease (inclusion allowed if status post nephroureterectomy and recurrence free at time of inclusion)
  • History of urothelial carcinoma of the prostate or urethra
  • History of muscle-invasive urothelial carcinoma of the bladder
  • History of pure squamous cell carcinoma of the bladder
  • Anatomic constraints that make standard cystoscopy impossible (e.g., history of urethrectomy, obliterated urethra secondary to stricture)
  • Small cell carcinoma of the bladder
  • Sarcoma of the bladder
  • Urothelial carcinoma with predominantly (>50%) variant histology
  • Eastern Cooperative Oncology Group (ECOG) performance status of 3 (capable of only limited selfcare; confined to bed or chair more than 50% of waking hours) or 4 (completely disabled; cannot carry out any selfcare; totally confined to bed or chair)
  • Unable to follow-up for planned minimum of 5 years (e.g., pending move away from their VA site, unless planned move is to another VATSIT study site)
  • Imaging concerning for metastatic urothelial carcinoma
  • Known pregnancy at the time of study enrollment (routine pregnancy testing is not required)

Where in United States

  • White River Junction VA Medical Center, White River Junction, VTWhite River Junction, United StatesContact: Florian R Schroeck, MD MSNot yet recruiting

About the trial

What the trial wants to find out

CSP #2036 is a pragmatic, randomized, intent-to-treat, two-arm, parallel, multicenter CSP trial. Blinding of clinical staff and participants will not be possible. However, outcomes will be adjudicated by assessors blinded to randomization arm to minimize bias. Due to the pragmatic nature of the study, treatment for bladder cancer will be at the discretion of the VA participants' clinicians, and all treatments will be recorded.

Read full original descriptionShow less

Veterans with high-grade non-muscle invasive bladder cancer who underwent biopsy or transurethral resection of a bladder tumor (TURBT) in the prior 6 months will be invited to participate. After a normal first cystoscopy after TURBT (also known as "3-month cystoscopy") and additional screening, participants will be randomized 1:1 to a program of low- vs high-intensity surveillance. Stratification by stage (2 groups: Ta only vs. any T1 / any Carcinoma in situ), and site will be done because these may influence other bladder cancer-specific care, such as the threshold of when to biopsy a possible bladder lesion and whether to administer intravesical therapy.

Outcomes will be assessed during study visits every three months for 24 months, every six months after that up to 48 months, and at 60 months. Follow-up data collection beyond 60 months will be completed by phone call or participants' health record review. This will be a 10-year study with 6 years dedicated to recruitment and a minimum of 4 years dedicated to follow-up. Thus, estimated average follow-up will be 7 years and maximum follow-up will be 10 years.

The 2 groups in the trial

  • Low Intensity SurveillanceTreatment being tested

    Participants assigned to low-intensity surveillance will undergo cystoscopy 12 months after transurethral resection, and then annually. They will also undergo non-invasive testing in the form of urine cytology every 3 months until month 24 after transurethral resection, then every 6 months until month 48, then annually

  • High Intensity SurveillanceOther group

    Participants assigned to high-intensity surveillance will undergo cystoscopy and urine cytology testing every 3 months until month 24 after transurethral resection, then every 6 months until month 48, then annually. This is the currently accepted surveillance schedule according to national guidelines and the VA National Oncology Bladder Cancer Clinical Pathway.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
CSP #2036 - VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High-Grade Bladder Tumors (VATSIT)
Plain-language title
Comparing less and more frequent check-ups after bladder tumor removal in veteransGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
13 February 2026